Yuefeng Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuefeng Yu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ningjian Wang
Department of Endocrinology and Metabolism, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, China
3 shared publications - Xiao Tan
Department of Psychiatry, Sir Run Shaw Hospital and Department of Big Data in Health Science, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications - Bin Wang
Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Ying Sun
Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200011
2 shared publications - Yingli Lu
Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Bowei Yu
Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong Special Administrative Region People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049815
Mosaic Loss of Chromosome Y, Smoking, and Risk of Symptomatic Peripheral Artery Disease: Insights From a Longitudinal Cohort Study
Background: Mosaic loss of chromosome Y (mLOY) has been linked to several cardiovascular diseases, but its association with peripheral artery disease (PAD) remains unclear. We examined the relationship between mLOY and symptomatic PAD. Methods: This longitudinal study included 217 047 men without prevalent PAD. mLOY was identified using the Mosaic Chromosomal Alterations pipeline. Incident symptomatic PAD was ascertained using International Classification of Diseases, Tenth Revision ( ICD‐10 ), and Office of Population Censuses and Surveys Classification of Interventions and Procedures, version 4 codes. Cox regression was used to evaluate the association between mLOY and PAD. We also performed exploratory mediation analyses of immune‐inflammatory biomarkers, examined the joint association of mLOY and smoking, and assessed the contribution of mLOY to sex‐related PAD disparities. Results: During a median follow‐up of 13.6 years, 4910 men developed symptomatic PAD. mLOY was associated with a higher risk of symptomatic PAD (hazard ratio [HR], 1.25 [95% CI, 1.17–1.33]; P P <0.001). Exploratory analyses suggested that several immune‐inflammatory biomarkers were statistically related to the mLOY‐PAD association. Additive‐scale interactions were observed between mLOY and former or current smoking. Compared with nonsmokers without mLOY, current smokers carrying mLOY had the highest PAD risk (HR, 4.69). Compared with matched women, men with mLOY had an ≈1.74‐fold higher PAD risk. Conclusions: mLOY was associated with symptomatic PAD, independently of other risk factors. These findings provide biologically informative evidence linking mLOY to symptomatic PAD and highlight smoking cessation as an important public‐health priority in men.
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049815
Open AccessMosaic Loss of Chromosome Y, Smoking, and Risk of Symptomatic Peripheral Artery Disease: Insights From a Longitudinal Cohort Study
Background: Mosaic loss of chromosome Y (mLOY) has been linked to several cardiovascular diseases, but its association with peripheral artery disease (PAD) remains unclear. We examined the relationship between mLOY and symptomatic PAD. Methods: This longitudinal study included 217 047 men without prevalent PAD. mLOY was identified using the Mosaic Chromosomal Alterations pipeline. Incident symptomatic PAD was ascertained using International Classification of Diseases, Tenth Revision ( ICD‐10 ), and Office of Population Censuses and Surveys Classification of Interventions and Procedures, version 4 codes. Cox regression was used to evaluate the association between mLOY and PAD. We also performed exploratory mediation analyses of immune‐inflammatory biomarkers, examined the joint association of mLOY and smoking, and assessed the contribution of mLOY to sex‐related PAD disparities. Results: During a median follow‐up of 13.6 years, 4910 men developed symptomatic PAD. mLOY was associated with a higher risk of symptomatic PAD (hazard ratio [HR], 1.25 [95% CI, 1.17–1.33]; P P <0.001). Exploratory analyses suggested that several immune‐inflammatory biomarkers were statistically related to the mLOY‐PAD association. Additive‐scale interactions were observed between mLOY and former or current smoking. Compared with nonsmokers without mLOY, current smokers carrying mLOY had the highest PAD risk (HR, 4.69). Compared with matched women, men with mLOY had an ≈1.74‐fold higher PAD risk. Conclusions: mLOY was associated with symptomatic PAD, independently of other risk factors. These findings provide biologically informative evidence linking mLOY to symptomatic PAD and highlight smoking cessation as an important public‐health priority in men.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (3) , e012145
Sweetened Beverages, Genetic Susceptibility, and Incident Atrial Fibrillation: A Prospective Cohort Study
BACKGROUND: An association between sweetened beverages and several cardiometabolic diseases has been reported, but their association with atrial fibrillation (AF) is unclear. We aimed to investigate the associations between consumption of sugar-sweetened beverages (SSB), artificially sweetened beverages (ASB), and pure fruit juice (PJ) and risk of consumption with AF risk and further evaluate whether genetic susceptibility modifies these associations. METHODS: A total of 201 856 participants who were free of baseline AF, had genetic data available, and completed a 24-hour diet questionnaire were included. Cox proportional hazard models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: During a median follow-up of 9.9 years, 9362 incident AF cases were documented. Compared with nonconsumers, individuals who consumed >2 L/wk of SSB or ASB had an increased risk of AF (HR, 1.10 [95% CI, 1.01–1.20] and HR, 1.20 [95% CI, 1.10–1.31]) in the multivariable-adjusted model. A negative association was observed between the consumption of ≤1 L/wk of PJ and the risk of AF (HR, 0.92 [95% CI, 0.87–0.97]). The highest HRs (95% CIs) of AF were observed for participants at high genetic risk who consumed >2 L/wk of ASB (HR, 3.51 [95% CI, 2.94–4.19]), and the lowest HR were observed for those at low genetic risk who consumed ≤1 L/wk of PJ (HR, 0.77 [95% CI, 0.65–0.92]). No significant interactions were observed between the consumption of SSB, ASB, or PJ and genetic predisposition to AF. CONCLUSIONS: Consumption of SSB and ASB at >2 L/wk was associated with an increased risk for AF. PJ consumption ≤1 L/wk was associated with a modestly lower risk for AF. The association between sweetened beverages and AF risk persisted after adjustment for genetic susceptibility to AF. This study does not demonstrate that consumption of SSB and ASB alters AF risk but rather that the consumption of SSB and ASB may predict AF risk beyond traditional risk factors.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (3) , e012145
Sweetened Beverages, Genetic Susceptibility, and Incident Atrial Fibrillation: A Prospective Cohort Study
BACKGROUND: An association between sweetened beverages and several cardiometabolic diseases has been reported, but their association with atrial fibrillation (AF) is unclear. We aimed to investigate the associations between consumption of sugar-sweetened beverages (SSB), artificially sweetened beverages (ASB), and pure fruit juice (PJ) and risk of consumption with AF risk and further evaluate whether genetic susceptibility modifies these associations. METHODS: A total of 201 856 participants who were free of baseline AF, had genetic data available, and completed a 24-hour diet questionnaire were included. Cox proportional hazard models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: During a median follow-up of 9.9 years, 9362 incident AF cases were documented. Compared with nonconsumers, individuals who consumed >2 L/wk of SSB or ASB had an increased risk of AF (HR, 1.10 [95% CI, 1.01–1.20] and HR, 1.20 [95% CI, 1.10–1.31]) in the multivariable-adjusted model. A negative association was observed between the consumption of ≤1 L/wk of PJ and the risk of AF (HR, 0.92 [95% CI, 0.87–0.97]). The highest HRs (95% CIs) of AF were observed for participants at high genetic risk who consumed >2 L/wk of ASB (HR, 3.51 [95% CI, 2.94–4.19]), and the lowest HR were observed for those at low genetic risk who consumed ≤1 L/wk of PJ (HR, 0.77 [95% CI, 0.65–0.92]). No significant interactions were observed between the consumption of SSB, ASB, or PJ and genetic predisposition to AF. CONCLUSIONS: Consumption of SSB and ASB at >2 L/wk was associated with an increased risk for AF. PJ consumption ≤1 L/wk was associated with a modestly lower risk for AF. The association between sweetened beverages and AF risk persisted after adjustment for genetic susceptibility to AF. This study does not demonstrate that consumption of SSB and ASB alters AF risk but rather that the consumption of SSB and ASB may predict AF risk beyond traditional risk factors.
- Top Cited PapersOpen Access
- 19 September 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (47) , 4982-4993
Acquired risk factors and incident atrial fibrillation according to age and genetic predisposition
Atrial fibrillation (AF) is the most common sustained arrhythmia in adults. Investigations of risk factor profiles for AF according to age and genetic risk groups are essential to promote individualized strategies for the prevention and control of AF. A total of 409 661 participants (mean age, 56 years; 46% men) free of AF at baseline and with complete information about risk factors were included from the UK Biobank cohort. The hazard ratios and population-attributable risk (PAR) percentages of incident AF associated with 23 risk factors were examined, including 3 social factors, 7 health behaviours, 6 cardiometabolic factors, 6 clinical comorbidities, and the genetic risk score (GRS), across 3 age groups (40–49, 50–59, and 60–69 years) and 3 genetic risk groups (low, moderate, and high GRS). After a follow-up of 5 027 587 person-years, 23 847 participants developed AF. Most cardiometabolic factors and clinical comorbidities showed a significant interaction with age, whereby the associations were generally strengthened in younger groups (Pinteraction < .002). However, only low LDL cholesterol, renal dysfunction, and cardiovascular disease showed a significant interaction with genetic risk, and the associations with these factors were stronger in lower genetic risk groups (Pinteraction < .002). Cardiometabolic factors consistently accounted for the largest number of incident AF cases across all age groups (PAR: 36.2%–38.9%) and genetic risk groups (34.0%–41.9%), with hypertension and overweight/obesity being the two leading modifiable factors. Health behaviours (PAR: 11.5% vs. 8.7%) and genetic risk factors (19.1% vs. 14.3%) contributed to more AF cases in the 40–49 years group than in the 60–69 years group, while the contribution of clinical comorbidities remained relatively stable across different age groups. The AF risk attributable to overall cardiometabolic factors (PAR: 41.9% in the low genetic risk group and 34.0% in the high genetic risk group) and clinical comorbidities (24.7% and 15.9%) decreased with increasing genetic risk. The impact of social factors on AF was relatively low across the groups by age and genetic risk. This study provided comprehensive information about age- and genetic predisposition-related risk factor profiles for AF in a cohort of UK adults. Prioritizing risk factors according to age and genetic risk stratifications may help to achieve precise and efficient prevention of AF. Age-specific and genetic predisposition-specific associations of risk factor profiles with atrial fibrillation (AF). Population-attributable risk percentages of AF risk factors were presented for different age and genetic risk population groups.
- 19 September 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (47) , 4982-4993
Top Cited PapersOpen AccessAcquired risk factors and incident atrial fibrillation according to age and genetic predisposition
Atrial fibrillation (AF) is the most common sustained arrhythmia in adults. Investigations of risk factor profiles for AF according to age and genetic risk groups are essential to promote individualized strategies for the prevention and control of AF. A total of 409 661 participants (mean age, 56 years; 46% men) free of AF at baseline and with complete information about risk factors were included from the UK Biobank cohort. The hazard ratios and population-attributable risk (PAR) percentages of incident AF associated with 23 risk factors were examined, including 3 social factors, 7 health behaviours, 6 cardiometabolic factors, 6 clinical comorbidities, and the genetic risk score (GRS), across 3 age groups (40–49, 50–59, and 60–69 years) and 3 genetic risk groups (low, moderate, and high GRS). After a follow-up of 5 027 587 person-years, 23 847 participants developed AF. Most cardiometabolic factors and clinical comorbidities showed a significant interaction with age, whereby the associations were generally strengthened in younger groups (Pinteraction < .002). However, only low LDL cholesterol, renal dysfunction, and cardiovascular disease showed a significant interaction with genetic risk, and the associations with these factors were stronger in lower genetic risk groups (Pinteraction < .002). Cardiometabolic factors consistently accounted for the largest number of incident AF cases across all age groups (PAR: 36.2%–38.9%) and genetic risk groups (34.0%–41.9%), with hypertension and overweight/obesity being the two leading modifiable factors. Health behaviours (PAR: 11.5% vs. 8.7%) and genetic risk factors (19.1% vs. 14.3%) contributed to more AF cases in the 40–49 years group than in the 60–69 years group, while the contribution of clinical comorbidities remained relatively stable across different age groups. The AF risk attributable to overall cardiometabolic factors (PAR: 41.9% in the low genetic risk group and 34.0% in the high genetic risk group) and clinical comorbidities (24.7% and 15.9%) decreased with increasing genetic risk. The impact of social factors on AF was relatively low across the groups by age and genetic risk. This study provided comprehensive information about age- and genetic predisposition-related risk factor profiles for AF in a cohort of UK adults. Prioritizing risk factors according to age and genetic risk stratifications may help to achieve precise and efficient prevention of AF. Age-specific and genetic predisposition-specific associations of risk factor profiles with atrial fibrillation (AF). Population-attributable risk percentages of AF risk factors were presented for different age and genetic risk population groups.